BioGenex's industry-leading next-generation cytogenetic FISH workflow solution and miRNA system for characterization of Cancer of Unknown Primary (CUP) and undifferentiated tumors are revolutionizing pathology. The company prides itself on delivering innovative products, years ahead of the competition in the field of immunohistochemistry (IHC) and in situ hybridization (ISH).
Cyborg Score Rationale
Proprietary fully-automated molecular pathology workstations from BioGenex are the most advanced systems available globally. The company has strong patent protections and a diversified global distribution network, but private company status and limited recent financial disclosure constrain visibility into growth trajectory and market share dynamics.
Top Insights
Product range includes primary antibodies, high sensitive detection kits, automated systems, probes, antigen retrieval systems, and histology stains.